Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05695781 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.
A Phase 3 study, sponsored by BRIM Biotechnology.
- Completed
- Registry status
- Phase 3
- Development phase
- 740
- Enrollment target
NCT05695781: Completed Phase 3 study, sponsored by BRIM Biotechnology.
NCT05695781 is a Phase 3 study that has completed, run by BRIM Biotechnology. The registered enrollment target is 740 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05695781, a Phase 3 study, has completed, sponsored by BRIM Biotechnology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 740 participants
- Enrollment target
Study Summary
The objective of this study is to compare the safety and efficacy of BRM421 OS to vehicle for the treatment of the signs and symptoms of dry eye disease.
Primary Outcome
0-12 Ora scale, higher scores mean a worse outcome.
Interventions
- DRUG Vehicle
- DRUG BRM421 Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2024-03-30 |
| Phase | Phase 3 |
What the finished NCT05695781 record still lists
NCT05695781 is an interventional study that assigns participants to a tested intervention. The registered 740 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT05695781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05695781 about?
NCT05695781 is a clinical study titled "Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.". The objective of this study is to compare the safety and efficacy of BRM421 OS to vehicle for the treatment of the signs and symptoms of dry eye disease.
What is the current status of trial NCT05695781?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 740 participants. The study started on 2023-02-27. Estimated completion is 2024-03-30.
What interventions are being tested in trial NCT05695781?
The interventions under investigation include: Vehicle (DRUG), BRM421 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05695781?
This trial is sponsored by BRIM Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05695781's enrollment target sits among peer trials
740 477th of 2000 higher than 1,523 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- NCT06172478 · 740 participants · Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI